Vorinostat-An overview

Indian Journal of Dermatology

Volumn 60, Issue 4, 2015, Pages 419-

  Bubna, Aditya Kumar ^a  

^a Kedar Hospital   (India)

Author keywords

Cutaneous T cell lymphoma; histone deacytelase inhibitor; Vorinostat

Indexed keywords

INTERLEUKIN DERIVATIVE; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER FATIGUE; CELL CYCLE ARREST; CHEMOTHERAPY INDUCED ANEMIA; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; DIARRHEA; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; FUTUROLOGY; GENETIC TRANSCRIPTION; HUMAN; LUNG EMBOLISM; POSTOPERATIVE NAUSEA AND VOMITING; QT PROLONGATION; REVIEW; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

EID: 84937956179     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.160511     Document Type: Review

References (39)

1. Zolinza (Vorinostat) Full Prescribing Information. White House Station, NJ: Merck and Co; 2006
2. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1: 194-202
3. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opin Investig Drugs 2005; 14: 1497-511
4. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188-93
5. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?. Cancer Cell 2003; 4: 13-8
6. Secrist JP, Zhou X, Richon VM. HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 2003; 4: 1422-7
7. Marks PA. Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochem Biophys Acta 2010; 1799: 717-25
8. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009; 107: 600-8
9. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32: 606-13
10. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 26729-34
11. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitors selectively induces p21WAF1 expression and gene-Associated histone acetylation. Proc Natl Acad Sci U S A 2000; 97: 10014-9
12. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, et al. P21-dependant g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83: 817-25
13. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through the activation of proapoptotic protein Bim. Proc Nactl Acad Sci U S A 2005; 102: 16090-5
14. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51
15. Bolden JE, Peart MJ, Johnstone RW. Anti-cancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-84
16. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transistion in vivo. Mol Cancer Ther 2010; 9: 3254-66
17. Rikiishi H. Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011; 2011: 830260
18. Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHAinduced apoptosis. Cell Death Differ 2006; 13: 129-40
19. Xu Y. Regulation of p53 responses by post-translational modifications. Cell Death Differ 2003; 10: 400-3
20. O'Connor OA. Developing new drugs for the treatment of lymphoma. Eur J Haematol Suppl 2005; 150-8
21. Lin EY, Pollard JW. Tumour-Associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007; 67: 5064-6
22. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, et al. Histone deacetylases induce angiogenesis by negative regulation of tumour suppressor genes. Nat Med 2001; 7: 437-43
23. Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, et al. The histone deacetylase inhibitors vorinostat and romidespin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 2011; 162: 1590-602
24. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, et al. HR23B is a biomarker for tumour sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A 2010; 107: 6532-7
25. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-31
26. Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucoronosyltransferase 1A1 polymorphisms: Are we there yet?. Pharmacotherapy 2008; 28: 755-68
27. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70
28. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP, et al. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005; 33: 53-61
29. Bulter LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165-70
30. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321-30
31. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, et al. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumours. Anticancer Res 2002; 22: 1497-504
32. Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrübl FA, Savaskan NE, Lüders M, et al. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 2005; 93: 992-9
33. Desai D, Das D, Cohen L, el Bayoumy K, Amin S. Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anticancer Res 2003; 23: 499-503
34. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247-52
35. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24: 166-73
36. Lansigan F, Choi J, Foss FM. Cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2008; 22: 979-96, x.
37. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9
38. Vorinostat (Zolinza) for cutaneous T-cell lymphoma. Med Lett Drugs Ther 2007; 49: 23-4
39. Wise LD, Turner KJ, Kerr JS. Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. Birth Defects Res B Dev Reprod Toxicol 2007; 80: 57-68